Article · Testing
When Exploratory Testing Produces Better Evidence Than a Script
When exploratory testing can reveal important failures, and how to keep its findings reviewable.
Sandip Thorat · 3 min read · Summary updated 2026-09-21 · Version 1.1
THE PRACTITIONER POSITION
The choice is not “documented testing” versus “undocumented testing.” The choice is which test design is most capable of exposing the failure that matters and producing reviewable evidence. A detailed script is excellent for repeatability, exact calculations, access rules, interfaces, and regulated record requirements. A structured exploratory charter is often stronger for complex workflows, unusual combinations, usability hazards, and emergent behavior.
SCRIPTED TESTING IS STRONGEST WHEN
- Inputs, expected results, and acceptance rules are deterministic
- Exact field values, calculations, permissions, or record states must be demonstrated
- A regression must be repeated consistently across releases
- The evidence must support a precise trace to a requirement or control
- Execution depends on a defined sequence that should not vary
UNSCRIPTED TESTING IS STRONGEST WHEN
- The failure space is larger than the known happy path
- Experienced users need freedom to follow anomalies
- Workflow behavior depends on state, history, timing, or user interpretation
- The design is new, rapidly changing, or only partly specified
- The concern is usability, overreliance, confusing feedback, or unexpected interaction
UNSCRIPTED DOES NOT MEAN UNCONTROLLED
A professional exploratory record identifies the mission, risk focus, system and configuration, tester, time box, test data, observations, evidence captured, issues, coverage achieved, and follow-up decisions. The tester records what was actually attempted rather than pretending every useful action was known in advance.
EXAMPLE CHARTER: DEVIATION WORKFLOW
Mission: Challenge whether a trained investigator can recognize and recover from conflicting record states without losing attribution or approval history.
Risk focus: simultaneous edits, reopened tasks, late attachments, role changes, browser interruption, stale sessions, and comments containing long text or special characters.
Method: Two testers use investigator and approver roles for 60 minutes. They vary sequence and timing, follow unexpected system behavior, and preserve screenshots, audit-trail extracts, record identifiers, and notes. Any observation affecting attribution, completeness, review, or approval becomes a formal issue or a targeted scripted follow-up.
HYBRID DESIGN
The strongest strategy frequently combines both modes. Use scripts to establish non-negotiable control points: electronic signature meaning, approval order, audit-trail creation, interface reconciliation, calculation accuracy, and permission boundaries. Use charters around those points to explore realistic misuse, interruptions, edge cases, and combinations. Convert a discovered critical defect into a repeatable regression test.
EVIDENCE REVIEW
Reviewers should ask whether the tester had appropriate domain knowledge, whether the charter targeted a credible risk, whether the evidence is attributable and contemporaneous, whether coverage and limitations are explicit, and whether observations produced accountable decisions. Page count is not an evidence-quality measure.
SCOPE AND LIMITATIONS
Exploratory testing is not a shortcut for weak requirements or a substitute for exact verification where an expected result is known. It requires skilled testers, disciplined capture, and clear governance. The balance should be justified from risk, complexity, novelty, and detectability.
Practitioner interpretation; apply the sources within their scope and follow your approved procedures. Original publication and source links are retained; this revision updates the summary and resource navigation.
Relevant regulations and guidance
These sources apply within their stated scope. The suggested worksheet fields, test designs and fictional decisions are practitioner recommendations, unless a source requirement is expressly identified. Completing a template does not establish compliance.
Regulatory guidance / GMP guideline · United States · February 2026
Scope: Medical-device manufacturers assuring software used in production or their quality management system.
Relevance: For medical-device production or QMS software, supports selecting assurance activities from intended use, risk and available evidence. It is nonbinding guidance and does not determine other sectors’ obligations.
Status: Final / published · Checked 2026-09-21
Publication identity, scope and status checked against the linked official source. This is not an independent audit of every retained guide statement.
Read source details and applicability →Regulatory guidance / GMP guideline · European Union · January 2011 revision
Scope: Computerised systems supporting activities in the applicable EU pharmaceutical GMP context.
Relevance: For computerised systems used in EU GMP activities, informs lifecycle, supplier and record controls. Confirm applicability to the actual activity; the example does not establish it.
Status: Final / published · Checked 2026-09-21
The Commission index confirms the January 2011 operative revision. The linked PDF could not be retrieved in this check; retained detailed section mappings need review against an authorized copy.
Read source details and applicability →Regulation · United States · Current eCFR text
Scope: Electronic records and signatures within FDA Part 11 scope, tied to the underlying required records.
Relevance: Assess applicability to electronic records required by FDA predicate rules and electronic signatures used in their place. The presence of an electronic record alone is not an applicability conclusion.
Status: Final / published · Checked 2026-09-21
Publication identity, scope and status checked against the linked official source. This is not an independent audit of every retained guide statement.
Read source details and applicability →